

# Stanford

---



## Ramamoorthy Nagasubramanian

Clinical Professor, Pediatrics - Hematology & Oncology

### CLINICAL OFFICE (PRIMARY)

- **Pediatric Hematology and Oncology**

725 Welch Rd Ste 224

MC 5798

Palo Alto, CA 94304

Tel (650) 497-8953 Fax (650) 497-8959

### Bio

---

#### CLINICAL FOCUS

- Pediatric Hematology-Oncology

#### ACADEMIC APPOINTMENTS

- Clinical Professor, Pediatrics - Hematology & Oncology

#### PROFESSIONAL EDUCATION

- Board Certification: Pediatric Hematology-Oncology, American Board of Pediatrics (2015)
- Board Certification: Pediatrics, American Board of Pediatrics (2015)
- Fellowship: University of Chicago Dept of Pediatrics (2002) IL
- Residency: University of Chicago Pediatric Residency (1995) IL
- Fellowship: University of Chicago Dept of Pediatrics IL
- Medical Education: Kilpauk Medical College (1988) India

### Publications

---

#### PUBLICATIONS

- **Factors Associated With Symptom Burden Among Pediatric Patients With Cancer.** *JCO oncology practice*  
Yan, A. P., Dupuis, L. L., Aftandilian, C., Agarwal, V., Baggott, C., Beauchemin, M. P., Bradfield, S. M., Cannone, D., Caywood, E. H., Crellin-Parsons, N., Demedis, J., Dickens, D., Esbenshade, et al  
2025: OP2500244
- **Factors Associated With Self-Report Symptom Screening Adherence in Pediatric Cancer Patients.** *Cancer medicine*  
Dupuis, L. L., Vettese, E., Aftandilian, C., Agarwal, V., Baggott, C., Bradfield, S. M., Crellin-Parsons, N., Freyer, D. R., Kelly, K. M., King, A. A., Kyono, W., Nagasubramanian, R., Orgel, et al  
2025; 14 (14): e71053
- **Care Pathway- and Guideline-Consistent Care in Pediatric Cancer Symptom Management.** *JCO oncology practice*

Crellin-Parsons, N., Dupuis, L. L., Vettese, E., Aftandilian, C., Agarwal, V., Baggott, C., Bradfield, S. M., Freyer, D. R., Kelly, K. M., King, A. A., Kyono, W., Nagasubramanian, R., Orgel, et al  
2025: OP2400912

- **Symptom Screening Linked to Care Pathways for Pediatric Patients With Cancer: A Randomized Clinical Trial.** *JAMA*  
Dupuis, L. L., Vettese, E., Grimes, A. C., Beauchemin, M. P., Klesges, L. M., Baggott, C., Demedis, J., Aftandilian, C., Freyer, D. R., Crellin-Parsons, N., Orgel, E., Dickens, D., Kelly, et al  
2024
- **Symptom management care pathway adaptation process and specific adaptation decisions.** *BMC cancer*  
Vettese, E., Sherani, F., King, A. A., Yu, L., Aftandilian, C., Baggott, C., Agarwal, V., Nagasubramanian, R., Kelly, K. M., Freyer, D. R., Orgel, E., Bradfield, S. M., Kyono, et al  
2023; 23 (1): 350
- **Quality of life of adults and children with TRK fusion cancer treated with larotrectinib compared to the general population.**  
Kummar, S., Van Tilburg, C. M., Albert, C. M., Berlin, J., Farago, A. F., McDermott, R. S., Bielack, S. S., Doz, F. P., DuBois, S. G., Lassen, U., Leyvraz, S., Mascarenhas, L., Nagasubramanian, et al  
AMER SOC CLINICAL ONCOLOGY.2020
- **Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1/2 clinical trials.** *The Lancet. Oncology*  
Hong, D. S., DuBois, S. G., Kummar, S. n., Farago, A. F., Albert, C. M., Rohrberg, K. S., van Tilburg, C. M., Nagasubramanian, R. n., Berlin, J. D., Federman, N. n., Mascarenhas, L. n., Geoerger, B. n., Dowlati, et al  
2020
- **Phase I and expanded access experience of LOXO-195 (BAY 2731954), a selective next-generation TRK inhibitor (TRKi)**  
Hyman, D., Kummar, S., Farago, A., Geoerger, B., Mau-Sorensen, M., Taylor, M., Garralda, E., Nagasubramanian, R., Natheson, M., Song, L., Capra, M., Jorgensen, M., Ho, et al  
AMER ASSOC CANCER RESEARCH.2019
- **Larotrectinib efficacy and safety in pediatric TRK fusion cancer patients.**  
van Tilburg, C., DuBois, S. G., Albert, C., Federman, N., Nagasubramanian, R., Geoerger, B., Orbach, D., Bielack, S. S., Shukla, N., Turpin, B., Casanova, M., Spunt, S. L., Qamoos, et al  
AMER SOC CLINICAL ONCOLOGY.2019
- **Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children** *NEW ENGLAND JOURNAL OF MEDICINE*  
Drilon, A., Laetsch, T. W., Kummar, S., DuBois, S. G., Lassen, U. N., Demetri, G. D., Nathenson, M., Doebele, R. C., Farago, A. F., Pappo, A. S., Turpin, B., Dowlati, A., Brose, et al  
2018; 378 (8): 731–39
- **Phase 1/2 study of the selective TRK inhibitor larotrectinib in pediatric patients with cancer**  
Federman, N., Albert, C., Turpin, B., Mascarenhas, L., Nagasubramanian, R., Geoerger, B., Casanova, M., Melcon, M., Chisholm, J., Van Tilburg, C. M., Shukla, N., Spunt, S. L., Cox, et al  
AMER SOC CLINICAL ONCOLOGY.2017